In conclusion, our data may have evident clinical implications, as they can be used to optimize the selection of HSC donors on the basis of immunogenetic KIR and HLA for ALL patients and identify the best NK cell subsets in immunotherapy to cure AML patients. The gene discussed is KIR3DL1; the disease is acute lymphoblastic leukemia.